Biotronik global managing director Werner Braun said Biotronik will fully utilise the accelerated development of the Asia Pacific countries to further propel the industry-leading growth trajectory that the company has maintained during previous years despite the global economic downturn.

"Our further plans for full-scale business development in Asia Pacific, which will be coordinated by a highly professional team based out of the new headquarters in Asia, are the latest milestone of many more to come for Biotronik and our customers in this region," Braun added.

Singapore Economic Development Board Biomedical Sciences deputy director Kevin Lai said they are excited that Biotronik has chosen Singapore to be its Asia Pacific headquarters. Singapore, with its strong regional connectivity and talent base, is well positioned as the strategic base to help companies access, manage and grow the diverse Asia Pacific market.

The company claims that short-term growth is expected to be driven by new and innovative product introductions such as the Orsiro, the company’s unique hybrid drug-eluting stent technology for coronary vascular intervention, and Lumax 740, the first ProMRI ICD for patients with tachycardia heart rhythm.